Summary & Overview
HCPCS J0270: Alprostadil Injection, 1.25 mcg
HCPCS Level II code J0270 denotes the injection of alprostadil, 1.25 mcg, administered under direct physician supervision rather than by patient self-administration. This code matters nationally because it specifies a provider-administered erectile dysfunction therapy formulation and delineates coverage and billing pathways distinct from self-injectable drug supplies. Accurate use of this code affects claims processing, site-of-service determinations, and payer medical necessity reviews.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how these payers typically classify provider-administered injectable drugs versus pharmacy-dispensed or self-administered formulations and the implications for reimbursement and documentation.
Readers will learn: the clinical context for alprostadil injection and typical outpatient settings where it is given; payer coverage considerations and common billing practices; coding nuances that influence claim adjudication; and benchmarks or policy updates relevant to provider-administered injectable drugs. Data not available in the input will be noted where applicable. The content is designed for national audiences involved in clinical billing, revenue cycle, and policy oversight.
Billing Code Overview
HCPCS Level II code J0270 describes the injection of alprostadil, 1.25 mcg. The code is used when the medication is administered by a clinician under direct physician supervision and is not intended for self-administration.
Service type: Medication injection (in-clinic/office-administered drug)
Typical site of service: Physician office, clinic, or other outpatient facility where direct supervision is provided
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A male patient with erectile dysfunction refractory to oral therapies presents to a urology clinic for intracavernosal injection therapy. The clinician prepares J0270 (alprostadil, 1.25 mcg) for administration under direct physician or supervising clinician observation. The encounter typically occurs in an outpatient clinic procedure room or ambulatory surgery center where the patient is positioned supine, the penis cleansed with antiseptic, and the clinician or trained nurse draws the medication into a syringe. The injection is administered into the corpora cavernosa, the patient is observed for immediate adverse events (pain, priapism, bleeding, dizziness), and post-injection monitoring continues until stable. Education is provided about potential delayed adverse events and return precautions. Documentation includes indication, informed consent, drug name and NDC if required, dosage (1.25 mcg per J0270), route (intracavernosal), supervising provider, and start/stop times for observation. This code is not used for self-administered therapy in home settings for Medicare billing because J0270 is reportable when the drug is administered under direct physician supervision in an institutional or clinic setting.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|